Spojené kráľovstvo - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - pergolide mesilate - oral tablet - 1mg

Spojené kráľovstvo - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - pergolide mesilate - oral tablet - 1mg

Spojené kráľovstvo - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - pergolide mesilate - oral tablet - 1mg

Spojené kráľovstvo - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

dr reddy's laboratories (uk) ltd - pergolide mesilate - oral tablet - 1mg

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

multichem nz limited - pergolide mesilate 0.0655mg equivalent to 0.05 mg pergolide - tablet - 0.05 mg - active: pergolide mesilate 0.0655mg equivalent to 0.05 mg pergolide excipient: iron oxide yellow magnesium stearate mannitol microcrystalline cellulose starch titanium dioxide - pergolide mesylate is indicated as second line therapy in patients who are intolerant or fail treatment with a non-ergot compound, as adjunctive treatment with levodopa in combination with decarboxylase inhibitors in the treatment of parkinson's disease. treatment should be initiated under specialist supervision. the benefit of continued treatment should be regularly reassessed taking into account the risk of fibrotic reactions and valvulopathy.

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

multichem nz limited - pergolide mesilate 0.3275mg equivalent to 0.25 mg pergolide - tablet - 0.25 mg - active: pergolide mesilate 0.3275mg equivalent to 0.25 mg pergolide excipient: magnesium stearate mannitol microcrystalline cellulose starch titanium dioxide - pergolide mesylate is indicated as second line therapy in patients who are intolerant or fail treatment with a non-ergot compound, as adjunctive treatment with levodopa in combination with decarboxylase inhibitors in the treatment of parkinson's disease. treatment should be initiated under specialist supervision. the benefit of continued treatment should be regularly reassessed taking into account the risk of fibrotic reactions and valvulopathy.

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

multichem nz limited - pergolide mesilate 1.31mg equivalent to 1 mg pergolide - tablet - 1 mg - active: pergolide mesilate 1.31mg equivalent to 1 mg pergolide excipient: iron oxide red magnesium stearate mannitol microcrystalline cellulose starch titanium dioxide - pergolide mesylate is indicated as second line therapy in patients who are intolerant or fail treatment with a non-ergot compound, as adjunctive treatment with levodopa in combination with decarboxylase inhibitors in the treatment of parkinson's disease. treatment should be initiated under specialist supervision. the benefit of continued treatment should be regularly reassessed taking into account the risk of fibrotic reactions and valvulopathy.

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd t/a gerard laboratories - pergolide mesilate - tablets - 1000 microgram

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd t/a gerard laboratories - pergolide mesilate - tablets - 50 microgram

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd t/a gerard laboratories - pergolide mesilate - tablets - 250 microgram